[The use of acetylsalicylic acid as a platelet antiaggregant].
OBJECTIVE
To comprove the efficiency of acetyl salicylic acid (ASA) as platelet antiaggregant drug, a 100 mg/day dose base.


METHODS
Two hundred and fifty-eight patients were studied between 1988 and 1990. Platelet functions were measured using an aggregometer plus ADP 5 as platelet aggregation inductor.


RESULTS
Two groups were studied: 1st group, using ASA (111 patients), 91 hypoaggregants; 2nd group, not using ASA (147 patients), 120 normals, 12 hypoaggregants and 15 hyperaggregants. From the 2nd group, 91 had another evaluation under the use of ASA and showed a clear effect of the drug.


CONCLUSIONS
The use of aspirin, 100 mg/day dose, is enough to reduce platelet antiaggregation.
de Araújo
A R
AR
Fundação de Hematologia e Hemoterapia de PE, Hospital das Clínicas, UFPE.
Sobreira
M I
MI
de Melo
G O
GO
Mendonca
C M
CM
Maranhão
E A
EA
Leite
M S
MS
Santos
F L
FL
D000293:Adolescent; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D002648:Child; D004341:Drug Evaluation; D006331:Heart Diseases / Q000097:blood / Q000188:drug therapy; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects
D001241:Aspirin
Uso do acido acetil salicílico como antiagregante plaquetário.